Positive Outcome of Sativex Phase III MS Study

 

Positive Outcome of Sativex Phase III MS Study

11  March  2009

GW Pharmaceuticals plc (GWP:AIM) today announces positive preliminary results from a pivotal Phase III double-blind randomised placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosis (MS), who have achieved inadequate spasticity relief with existing therapies. This study was requested by the UK regulator in order to gain approval in this indication and following today's results, GW will file a regulatory submission in Q2 09.

Expected Milestone Payment from Almirall of GBP8m

This Phase III study used an enriched design whereby 573 patients initially received Sativex for 4 weeks in a single blind manner (Phase A), following which Sativex responders (n=241) were randomized to continue on Sativex or switch to placebo for a further 12 weeks in a double-blinded manner (Phase B). During the randomized period, patients were not permitted to adjust their dose. This study is the largest study GW has undertaken and recruitment was achieved in just ten months using 52 hospital sites in five countries - UK, Spain, Italy, Czech Republic and Poland.

The prospectively defined primary efficacy endpoint of the study - the difference between the mean change in spasticity severity of Sativex vs Placebo in Phase B - was highly statistically significantly in favour of Sativex (p=0.0002). The numeric difference between the two groups as measured on a Numeric Rating Scale was 0.84 units from a baseline of 3.89, greater than that achieved in previous studies. The difference between Sativex and placebo was also significant for a number of secondary endpoints. 74% of Sativex patients achieved an improvement of greater than 30% in their spasticity score over the entire study versus 51% on placebo (p=0.0003). In addition, statistically significant improvements were also seen in spasm frequency (p=0.005), sleep disturbance (p<0.0001), patient global impression of change (p=0.023), and physician global impression of change (p=0.005).

The study provides further evidence of Sativex's reassuring safety profile. The adverse event data in this study was superior to previous Sativex studies - an improvement which resulted from the modified dose titration regimen employed in the study.

Following these positive results, GW will submit a regulatory application in Q2 09 in the UK and, subject to discussion with Almirall, other selected European countries. Upon approval, Sativex will be marketed exclusively in the UK by Bayer HealthCare and in the rest of Europe by Almirall.

Dr Stephen Wright, GW's R&D Director, said: "This Phase III study is a resounding success and provides further evidence that Sativex provides meaningful efficacy for people with spasticity due to MS. In the last six months, GW has reported three positive Sativex studies incorporating a design modified from previous studies and we are delighted that this new approach is producing such consistent positive results. We will file a European regulatory submission in Q2 09 and look forward to progressing the review during 2009."

Milestone Payment

GW also announces today that it has signed an amendment to the Sativex licence agreement with Almirall. This amendment provides for the potential milestone payment to be received following this study result to reach GBP8m. The GBP8m milestone will become due upon Almirall electing to include a country within their licensed territory (Europe excluding UK) as part of the forthcoming regulatory submission to the UK. This decision is expected to be made within the next month.

Justin Gover, GW's Managing Director, said, "GW has a history of maintaining a strong financial position and this increased potential milestone payment represents an attractive opportunity to further consolidate this position. We are delighted by the ongoing support and enthusiasm of our licensing partners for the commercial potential of Sativex."

There will be a conference call for analysts today at 2.30pm and the corresponding presentation will be available on the investor relations section of the GW website (www.gwpharm.com). Analysts should contact Juliet Edwards at Financial Dynamics on 020 7269 7125 for details. A recording of this meeting will be available on the GW website later today.

Enquiries:

Enquiries:

GW Pharmaceuticals pl:(Today)+ 44 20 7831 3113

Dr Geoffrey Guy, Executive Chairman: (Thereafter) + 44 1980 557000

Justin Gover, Managing Director

Financial Dynamics:+ 44 20 7831 3113

David Yates / John Dineen

Investec Bank plc:+ 44 20 7597 4000

Patrick Robb


Notes to Editors

Sativex Prescription Use
Sativex is approved and marketed in Canada for the treatment of cancer pain and
MS neuropathic pain. In addition, Sativex is available on prescription in the UK
on a "named patient" basis and has to date been exported to 22 countries around
the world.

Sativex and MS Spasticity
Spasticity (spasms and stiffness) is one of the most common symptoms of MS
occurring in as many as three-quarters of people with MS. Spasticity can affect
many aspects of daily life, such as walking and sitting. Sativex aims to treat
high need patients who have previously failed to gain adequate benefit from
currently available anti-spasticity treatments

The indication of MS spasticity has been the sole focus of previous discussions
with European regulatory authorities. The trial reported today was specifically
requested by the UK regulator, the Medicines and Healthcare products Regulatory
Agency (MHRA), prior to obtaining approval for Sativex.

Prior to the study reported today, GW had accumulated a body of clinical data in
approximately 700 patients with MS spasticity, including two pivotal Phase III
trials as well as two supportive trials.


In February 2009, GW reported positive results from a placebo-controlled
randomized withdrawal study of Sativex  in patients with spasticity due to MS.
This study showed that Sativex provides meaningful long term efficacy for people
with spasticity due to MS, and will be important additional feature of the
efficacy and safety data to be submitted in the forthcoming regulatory
application.

GW expects to file a regulatory submission in Q2 09. Upon UK approval, GW will
receive a GBP10m milestone payment from Bayer. On approval in Spain, GW will
receive a further GBP2.5m payment from Almirall.

Sativex and Cancer Pain
Over one-third of patients with cancer, and more than three-quarters of those
with advanced disease, have chronic pain.  Currently available opioid therapies
do not yield sufficient relief in a substantial proportion of these patients and
there is a clear need for new treatments.

Cancer pain is the lead indication for the development of Sativex in the United
States. GW has completed a positive Phase II cancer pain study in Europe in 177
patients and is now carrying out a 336 patient Phase IIb/III study in
collaboration with its partner, Otsuka Pharmaceutical Co. Ltd. Upon approval,
Sativex will be exclusively marketed in the US by Otsuka.

About GW
GW was founded in 1998 and listed on the AiM, a market of the London Stock
Exchange, in June 2001. Operating under license from the UK Home Office, the
company researches and develops cannabinoid pharmaceutical products for patients
who suffer from a range of serious ailments, in particular multiple sclerosis
and cancer pain. GW has assembled a large in-house scientific team with
expertise in cannabinoid science as well as experience in the development of
both plant-based prescription pharmaceutical products and medicines containing
controlled substances. GW occupies a world leading position in cannabinoids and
has developed an extensive international network of the most prominent
scientists in the field.